<DOC>
	<DOCNO>NCT03072823</DOCNO>
	<brief_summary>N-3 polyunsaturated fatty acid ( N-3 PUFAs ) important balance immune function physical health reduce membrane arachidonic acid ( AA ) prostaglandin E2 ( PGE2 ) synthesis , might link somatic manifestation physical morbidity , Cardiovascular disease depression . n-3 polyunsaturated fatty acid appear promising treatment safe , beneficial patient Cardiovascular disease depression . In proposal , investigator aim test hypothesis n-3 polyunsaturated fatty acid effective placebo treat Cardiovascular disease patient major depression 12 week intervention .</brief_summary>
	<brief_title>Omega-3 Polyunsaturated Fatty Acids Major Depressive Disorder Patients With Cardiovascular Diseases</brief_title>
	<detailed_description>This 3-year study randomize , double-blind , placebo control Clinical study . investigator plan enroll 60 subject cardiovascular department China Medical University Hospital.Participants randomize omega-3 polyunsaturated fatty acid placebo group.The intervention period 12 week . Evaluation depressive symptom ( use Hamilton Depression Scale , HAM-D , Beck Depression Inventory , BDI ) subject enrolled study take place â€”1st , 0 , 2nd , 4th , 8th , 12th week . The plasma level n-3 polyunsaturated fatty acid , chemokines/cytokines , Electrocardiogram also measure begin end study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Cardiovascular disease patient 2 . The Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criteria major depressive disorder . 3 . Capacity willingness give write informed consent . 1. cognitive impairment ( Minimental state examination score &lt; 24 ) 2. comorbid psychiatric disorder , psychosis , high risk suicide , current substance use 3. acute coronary syndrome within previous 2 month , leave ventricular ejection fraction ( LVEF ) &lt; 30 % , advanced malignancy , physical inability participate 4. use antidepressant , anticonvulsant , lithium , n3 polyunsaturated fatty acid supplement 5. coagulation disorder sensitivity n3 polyunsaturated fatty acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CVDs</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>n-3 polyunsaturated fatty acid</keyword>
	<keyword>depression</keyword>
</DOC>